Ignite Creation Date:
2025-12-25 @ 3:57 AM
Ignite Modification Date:
2025-12-26 @ 2:48 AM
Study NCT ID:
NCT06106802
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-10-30
First Post:
2023-10-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Sponsor:
Samsung Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-02-02
Start Date Type:
ESTIMATED
Primary Completion Date:
2029-09-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-12
First Submit QC Date:
None
Study First Post Date:
2023-10-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-27
Last Update Post Date:
2023-10-30
Last Update Post Date Type:
ACTUAL